enGene Therapeutics Inc. (ENGN) income statement
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.85+0.13 (+7.56%)
Close on Nov 18, 2026Market cap $123.98MP/E –Yield 0.00%
enGene Therapeutics Inc. income statement
Ratios
Latest available, balances at Jul 31, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -53.3%
Financial strength
- Current ratio
- 10.21
- Debt to equity
- 0.11
- Debt to assets
- 8.7%
- Cash to current liabilities
- 150.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.54
- Dividend yield
- 0.00%
See a number that looks wrong?